International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
A Phase IB/IIA, Open-Label Study Of The Safety, Pharmacokinetics, And Pharmacodynamics Of Fosciclopirox Alone And In Combination With Cytarabine In Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Phase I Study of DS-3032B in Combination with Quizartinib in Subjects with FLT3-ITD Mutant Acute Myeloid Leukemia That are Relapsed/Refractory, or Newly Diagnosed and Unfit for Intensive Chemotherapy
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Dociparstat Sodium in Combination with Standard Chemotherapy for the Treatment of Newly-Diagnosed Acute Myeloid Leukemia
BLockade of PD-1 Added to Standard Therapy to target Measurable Residual Disease
in Acute Myeloid Leukemia 2 BLAST MRD AML-2: A randomized Phase 2 Study of the
Venetoclax, Azacitidine, and Pembrolizumab VAP Versus Venetoclax and Azacitidine as First
Line Therapy in Older Patients with Acute Myeloid Leukemia AML who are Ineligible or who
Refuse Intensive Chemotherapy
A Phase 1/2, Multi-Center, Open-Label, Single-Arm, Dose-Escalation, Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetics PK And Anti-Tumor Activity of FN-1501 Monotherapy In Patients with Advanced Solid Tumors or Relapsed/Refractory Acute Myeloid Leukemia AML
An Open-Label, Phase I, Multi-Center Study to Determine in Relapsed/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome or B-Cell Non-Hodgkin Lymphoma Patients the Recommended Dose of CYAD-02 After A Non-Myeloablative Preconditioning Chemotherapy Followed By A Potential CYAD-02 Consolidation Cycle for Non-Progressive Patients CYCLE-1 ? CYAD-02 NKG2D CAR-T Clinical dEvelopment